Analyst firms · UBS · CYTK
UBS CYTK price target and rating history
Cytokinetics Incorporated (CYTK) · Health Care
UBS rates Cytokinetics Incorporated (CYTK) Buy with a $115 price target, as of its latest action on Jun 29, 2026. It has published 3 rating actions on CYTK since October 2022, including 1 upgrade and 1 downgrade. Across 5 firms with a CYTK price target in the last 12 months, the median target is $95. UBS's $115 is 21% above that.
- Current rating
- Buy
- Price target
- $115
- Median target, all firms
- $95
- Actions on CYTK
- 3
UBS price target on CYTK
Every UBS rating on CYTK
- Jun 29, 2026
- Jan 24, 2024
- Oct 11, 2022
How other firms rate CYTK
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| UBS | Buy | $115 | Jun 29, 2026 |
| Citigroup | Buy | $99 | May 19, 2026 |
| Wells Fargo | Overweight | $95 | Apr 10, 2026 |
| Barclays | Overweight | $87 | Jan 28, 2026 |
| Goldman Sachs | Buy | $95 | Dec 18, 2025 |
Questions about UBS and CYTK
- What is UBS's price target for CYTK?
- UBS's latest stated price target for Cytokinetics Incorporated (CYTK) is $115, from its action on Jun 29, 2026.
- What is UBS's rating on CYTK?
- UBS rates CYTK Buy, a bullish rating, as of Jun 29, 2026.
- When did UBS last change its view on CYTK?
- On Jun 29, 2026, UBS upgrades to Buy from Neutral, price target $115.
- How does UBS's CYTK target compare with other analysts?
- Across 5 firms with a CYTK price target in the last 12 months, the median target is $95. UBS's $115 is 21% above that.
More CYTK rating histories
All UBS ratingsCYTK news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.